Lescol and Lescol XL are indicated for the treatment of hypercholesterolemia and mixed hyperlipidemia in conjunction with a diet low in saturated fat and cholesterol.
Lescol is also indicated for the secondary prevention of cardiovascular events in patients with coronary heart diseases who have undergone a percutaneous coronary intervention (PCI) procedure.
Under the terms of the agreement – which will run through 2008 – Biovail will promote Lescol 20mg and 40mg capsules and once-daily Lescol XL 80mg extended-release tablets for a fee based on a percentage of Novartis' net selling price over mutually determined performance baselines
“Lescol reduces 'bad' LDL cholesterol and increases 'good' HDL cholesterol in the blood which, in turn, can help to lower the risk of atherosclerosis and heart disease,” said Doug Herman, vice-president and general manager of Biovail Pharmaceuticals Canada.